Cencora vs Cvs Health
COR and CVS side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How COR and CVS compare
Cvs Health is the larger company, worth 1.8 times as much as Cencora ($115B against $63.1B).
On earnings, Cvs Health is cheaper: it trades at 23.9× trailing earnings, against 24.6× for Cencora.
Cvs Health grew revenue faster over the last twelve months (7.4% versus 5.1% for Cencora).
Cvs Health keeps more of each dollar of sales as profit, with a net margin of 1.2% compared with 0.79% at Cencora.
Both pay dividends: Cencora yields 0.73% and Cvs Health 2.2%.
Cencora scores higher on the StockData Score (15 against 12 for Cvs Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | COR | CVS |
|---|---|---|
| Size and price | ||
| Market cap | $63.1B | $115B |
| Share price | $330.84 | $90.25 |
| Change, 1 year | −0.70% | 12.0% |
| Change, 5 years | 159% | −3.8% |
| Beta (5Y) | 0.33 | 0.47 |
| Employees | 51K | 300K |
| StockData Score | ||
| Total score | 15 (better) | 12 |
| Valuation score | 1 | 1 |
| Growth score | 3 | 3 |
| Performance score | 5 (better) | 2 |
| Health score | 2 | 2 |
| Dividend score | 4 | 4 |
| Valuation | ||
| P/E | 24.6× | 23.9× (better) |
| P/S | 0.2× (better) | 0.3× |
| P/B | 20.7× | 1.4× (better) |
| EV/EBITDA | 17.7× | 12.7× (better) |
| P/FCF | 15.5× | 9.8× (better) |
| FCF yield | 6.4% | 10.2% (better) |
| Fair value | $287.88 | $77.92 |
| Margin of safety | −14.9% (better) | −15.8% |
| Growth | ||
| Revenue growth (TTM) | 5.1% | 7.4% (better) |
| Revenue growth, 5Y average | 11.1% (better) | 8.4% |
| Net income growth (TTM) | 38.3% (better) | 7.9% |
| EPS growth (TTM) | 38.6% (better) | 5.3% |
| EPS growth, 5Y average | – | −23.9% |
| Profitability | ||
| Gross margin | 4.0% | 44.5% (better) |
| Operating margin | 0.91% | 2.0% (better) |
| Net margin | 0.79% | 1.2% (better) |
| FCF margin | 1.2% | 2.8% (better) |
| Return on equity | 104% (better) | 6.2% |
| Return on invested capital | 22.3% (better) | 5.5% |
| Financial health | ||
| Debt / equity | 3.84 | 0.77 (better) |
| Net debt / EBITDA | 2.18 (better) | 3.70 |
| Interest coverage | – | 2.7× |
| Current ratio | 0.93 (better) | 0.87 |
| Altman Z-score | 4.66 (better) | 2.45 |
| Piotroski F-score | 7 | 7 |
| Dividends and buybacks | ||
| Dividend yield | 0.73% | 2.2% (better) |
| Payout ratio | 17.8% | 69.9% |
| Years of dividend growth | 16 (better) | 0 |
| Dividend growth, 5Y average | 5.8% | 5.9% (better) |
| Buyback yield | 1.6% | – |
| Shareholder yield | 2.3% (better) | 2.2% |
| Ownership | ||
| Held by institutions | 96.1% | 89.2% |
| Held by insiders | 5.4% | 0.43% |
| Insider net buying, 12 months | −$12.4M (better) | −$324M |
| Superinvestors holding | – | 6 |
| Short interest, % of float | 2.2% | 1.3% |
Go deeper
- COR stock overview
- COR income statement
- COR valuation and score
- CVS stock overview
- CVS income statement
- CVS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.